ME00598B - Bakterini tretirani toplotom i vakcine tipa emulzije izrađene od ovakvih bakterina tretiranih toplotom - Google Patents
Bakterini tretirani toplotom i vakcine tipa emulzije izrađene od ovakvih bakterina tretiranih toplotomInfo
- Publication number
- ME00598B ME00598B MEP-2009-75A MEP7509A ME00598B ME 00598 B ME00598 B ME 00598B ME P7509 A MEP7509 A ME P7509A ME 00598 B ME00598 B ME 00598B
- Authority
- ME
- Montenegro
- Prior art keywords
- bacterin
- leptospira
- lipase activity
- approximately
- heat
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract 11
- 239000000839 emulsion Substances 0.000 title claims abstract 3
- 241000894006 Bacteria Species 0.000 claims abstract 9
- 238000000034 method Methods 0.000 claims abstract 5
- 238000010438 heat treatment Methods 0.000 claims 21
- 235000019626 lipase activity Nutrition 0.000 claims 17
- 241000700605 Viruses Species 0.000 claims 13
- 241000589902 Leptospira Species 0.000 claims 12
- 239000000725 suspension Substances 0.000 claims 6
- 241000283690 Bos taurus Species 0.000 claims 4
- 241000711895 Bovine orthopneumovirus Species 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 241001550390 Leptospira interrogans serovar Canicola Species 0.000 claims 3
- 241000589926 Leptospira interrogans serovar Hardjo Species 0.000 claims 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 2
- 206010051497 Rhinotracheitis Diseases 0.000 claims 2
- 206010051511 Viral diarrhoea Diseases 0.000 claims 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 229940067606 lecithin Drugs 0.000 claims 2
- 235000010445 lecithin Nutrition 0.000 claims 2
- 239000000787 lecithin Substances 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Otkriveni su bakterini tretirani toplotom, postupak za dobijanje bakterina tretiranih toplotom i emulzione vakcine izrađene od ovih bakterina tretiranih toplotom.
Claims (22)
1.Bakterin tretiran toplotom, naznačen time što uključuje suspenziju ubijenih bakterija koji imaju lipaza aktivnost 50% ili manju od lipaza aktivnosti bakterina pre tretmana toplotom.
2.Bakterin tretiran toplotom, u skladu sa patentnim zahtevom l, naznačen time što tretman toplotom uključuje zagrevanje bakterina koji ima lipaza aktivnost na temperaturu od približno 35 do približno 80 °C, u toku približno 20 minuta do približno 24 sata.
3.Bakterin tretiran toplotom, u skladu sa patentnim zahtevom l, naznačen time što tretman toplotom uključuje zagrevanje bakterina koji ima lipaza aktivnost na temperaturu od približno 60 do približno 70 °C, u toku približno 9 do približno l O sati.
4.Bakterin tretiran toplotom, u skladu sa patentnim zahtevom l , naznačen time što tretman toplotom uključuje zagrevanje bakterina koji ima lipaza aktivnost na temperaturu od približno 65 do približno 70 °C, u toku približno 5 do približno 8 sati.
5.Bakterin tretiran toplotom, koji uključuje suspenziju ubijene bakterije, u skladu sa patentnim zahtevom l, naznačen time što tretman toplotom uključuje: zagrevanje bakterina koji ima lipaza aktivnost na temperaturu od približno 65 do približno 70 °C, u toku približno l sat.
6.Bakterin tretiran toplotom, koji uključuje suspenziju ubijene bakterije, u skladu sa patentnim zahtevom l , naznačen time što tretman toplotom uključuje: zagrevanje bakterina koji ima lipaza aktivnost na temperaturu od približno 55 do približno 65 °C, u toku približno 5 do približno 8 sati.
7.Bakterin tretiran toplotom, koji uključuje suspenziju ubijene bakterije, u skladu sa patentnim zahtevom 2, naznačen time što je ubijena bakterija jedna od pet Leptospira vrsta izabrana iz grupe koja sadrži Leptospira canicola, Leptospira grippotyposa, Leptospira hardjo, Leptospira icterohaemorrhagiae i Leptospira pomona.
8.Vakcina naznačena time što uključuje emulziju i bakterin tretiran toplotom, u skladu sa patentnim zahtevom 2.
9.Vakcina u skladu sa patentnim zahtevom 8, naznačena time što dalje uključuje žive viruse.
10.Vakcina u skladu sa patentnim zahtevom 8, naznačena time što dalje uključuje preparat lecitina, Quil A i holesterol.
11.Vakcina u skladu sa patentnim zahtevom 8, naznačena time što dalje uključuje ubijene viruse.
12.Vakcina u skladu sa patentnim zahtevom 9, naznačena time što dalje uključuje ubijene viruse.
13.Vakcina u skladu sa patentnim zahtevom 9, naznačena time što su živi virusi jedan od tri virusa izabrana iz grupe koja sadrži goveđi rinotraheitis (IBR) virus, parainfluenca 3 (PB) virus i goveđi respiratorni sinctijalni virus (BRSV).
14.Vakcina u skladu sa patentnim zahtevom 12, naznačena time što su živi virusi jedan od tri virusa izabrana iz grupe koja sadrži goveđi rinotraheitis (IBR) virus, parainfluenca 3 (PB) virus i goveđi respiratorni sinctijalni virus (BRSV).
15.Vakcina u skladu sa patentnim zahtevom 14, naznačena time što su ubijeni virusi jedan ili dva virusa izabrana iz grupe koja sadrži Tip l goveđe virusne dijareje (BVD) i Tip 2 goveđe virusne dijareje (BVD)
16.Vakcina u skladu sa patentnim zahtevom 15, naznačena time što dalje uključuje preparat lecitina u ulju, Quil A i holesterol.
17.Postupak za izradu bakterina tretiranog toplotom, naznačen time što uključuje zagrevanje bakterina koji ima lipaza aktivnost na temperaturu od približno 35 do približno 80 °C, u toku približno 20 minuta do približno 24 sata.
18. Postupak za izradu bakterina tretiranog toplotom, naznačen time što uključuje a) merenje lipaza aktivnosti bakterina; b) zagrevanje bakterina na temperaturu od približno 35 do približno 80 °C, u toku približno 20 minuta do približno 24 sata; e) merenje lipaza aktivnosti bakterina nakon tretmana toplotom; d) upoređivanje lipaza aktivnosti bakterina pre zagrevanja sa lipaza aktivnošću bakterina nakon zagrevanja; e) izbor bakterina tretiranog toplotom, pri čemu je lipaza aktivnost nakon tretmana toplotom 50% ili manja od lipaza aktivnosti bakterina pre tretmana toplotom.
19.Postupak u skladu sa patentnim zahtevom 17, naznačen time što bakterin uključuje suspenziju odjedne do pet ubijenih Leptospira vrsta izabranih iz grupe koja sadrži Leptospira canicola, Leptospira grippotyposa, Leptospira hardjo, Leptospira icterohaemorrhagiae i Leptospira pomona.
20.Postupak u skladu sa patentnim zahtevom 18, naznačen time što bakterin uključuje suspenziju odjedne do pet ubijenih Leptospira vrsta izabranih iz grupe koja sadrži Leptospira canicola, Leptospira grippotyposa, Leptospira hardjo, Leptospira icterohaemorrhagiae i Leptospira pomona.
21.Bakterin tretiran toplotom izrađen pomoću: a) formiranja bakterina koji ima lipaza aktivnost; b) zagrevanja bakterina na temperaturu od približno 35 do približno 80 °C, u vremenskom periodu koji je dovoljan da smanji lipaza aktivnost do vrednosti od 50% ili manje od vrednosti pre tretmana toplotom.
22.Bakterin u skladu sa patentnim zahtevom 21, naznačen time što je vremenski period dovoljan da smanji lipaza aktivnost do nivoa od 50% ili manje od nivoa pre tretmana toplotom, približno 20 minuta do približno 24 sata.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84366506P | 2006-09-11 | 2006-09-11 | |
| PCT/IB2007/002553 WO2008032158A2 (en) | 2006-09-11 | 2007-08-30 | Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MEP7509A MEP7509A (en) | 2011-12-20 |
| ME00598B true ME00598B (me) | 2011-12-20 |
Family
ID=39110574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2009-75A ME00598B (me) | 2006-09-11 | 2007-08-30 | Bakterini tretirani toplotom i vakcine tipa emulzije izrađene od ovakvih bakterina tretiranih toplotom |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8491915B2 (me) |
| EP (2) | EP2066340B1 (me) |
| JP (2) | JP5550341B2 (me) |
| KR (1) | KR101238486B1 (me) |
| CN (1) | CN101516393B (me) |
| AR (1) | AR062758A1 (me) |
| AU (1) | AU2007297287B2 (me) |
| BR (1) | BRPI0716548B1 (me) |
| CA (1) | CA2663166C (me) |
| CL (1) | CL2007002621A1 (me) |
| CO (1) | CO6160333A2 (me) |
| DK (2) | DK2377550T3 (me) |
| ES (2) | ES2535977T3 (me) |
| ME (1) | ME00598B (me) |
| MX (1) | MX2009001849A (me) |
| NO (1) | NO339147B1 (me) |
| NZ (2) | NZ574896A (me) |
| PL (2) | PL2377550T3 (me) |
| PT (1) | PT2066340E (me) |
| RS (1) | RS54981B1 (me) |
| RU (2) | RU2425692C2 (me) |
| SI (1) | SI2066340T1 (me) |
| TW (1) | TWI361077B (me) |
| UA (1) | UA98115C2 (me) |
| WO (1) | WO2008032158A2 (me) |
| ZA (1) | ZA200902493B (me) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101254848B1 (ko) * | 2007-12-21 | 2013-04-15 | 화이자 인코포레이티드 | 열 처리된 박테린, 및 상기 열 처리된 박테린으로부터 제조된 에멀젼 백신 |
| EP2717055A1 (en) * | 2012-10-04 | 2014-04-09 | Institut Pasteur | Use of Leptospira fainei serovar Hurstbridge bacteria for diagnosing leptospirosis |
| EP4237075A4 (en) * | 2020-05-26 | 2024-12-04 | Cyrus 21st Century Entrepreneurship LLC | KAKIM POUR CINA'S G AND ZODA-E |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3721169A1 (de) * | 1986-06-30 | 1988-01-14 | Lion Corp | Orale zubereitung |
| US5084269A (en) | 1986-11-06 | 1992-01-28 | Kullenberg Fred W | Adjuvant for dose treatment with antigens |
| RU2030915C1 (ru) * | 1990-10-31 | 1995-03-20 | Всероссийский государственный научно-исследовательский институт контроля, стандартизации и сертификации ветеринарных препаратов | Вакцина против лептоспироза животных |
| US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| AU2001234616A1 (en) | 2000-01-31 | 2001-08-07 | Vic Jira | Vaccine composition, process and methods |
| US20030147914A1 (en) | 2001-07-02 | 2003-08-07 | Pfizer Inc. | Mycoplasma bovis vaccine and methods of reducing pneumonia in animals |
| RS20050177A (sr) | 2002-08-26 | 2007-06-04 | Pfizer Products Inc., | Vakcina za infekcije respiratornog i reproduktivnog sistema kod stoke |
| WO2004026024A2 (en) | 2002-09-20 | 2004-04-01 | The United States Of America As Represented By The Secretary Of Agriculture | Vaccine compositions and adjuvant |
| AU2002951692A0 (en) | 2002-09-23 | 2002-10-17 | Vital Biotech (Hong Kong) Limited | Improvements in or relating to vaccines |
| MXPA05008051A (es) * | 2003-01-29 | 2005-09-21 | Pfizer Prod Inc | Vacunas caninas contra bordetella bronchiseptica. |
| AU2004226591B2 (en) * | 2003-04-04 | 2009-06-04 | Zoetis Services Llc | Microfluidized oil-in-water emulsions and vaccine compositions |
-
2007
- 2007-08-30 EP EP07804880.8A patent/EP2066340B1/en active Active
- 2007-08-30 CA CA2663166A patent/CA2663166C/en active Active
- 2007-08-30 PL PL11173797T patent/PL2377550T3/pl unknown
- 2007-08-30 DK DK11173797T patent/DK2377550T3/en active
- 2007-08-30 BR BRPI0716548-0A patent/BRPI0716548B1/pt active IP Right Grant
- 2007-08-30 SI SI200731337T patent/SI2066340T1/sl unknown
- 2007-08-30 MX MX2009001849A patent/MX2009001849A/es active IP Right Grant
- 2007-08-30 KR KR1020097004968A patent/KR101238486B1/ko active Active
- 2007-08-30 NZ NZ574896A patent/NZ574896A/en unknown
- 2007-08-30 JP JP2009527907A patent/JP5550341B2/ja active Active
- 2007-08-30 ES ES11173797.9T patent/ES2535977T3/es active Active
- 2007-08-30 RS RS20090088A patent/RS54981B1/sr unknown
- 2007-08-30 ES ES07804880T patent/ES2432392T3/es active Active
- 2007-08-30 PT PT78048808T patent/PT2066340E/pt unknown
- 2007-08-30 RU RU2009108004/10A patent/RU2425692C2/ru active
- 2007-08-30 UA UAA200902099A patent/UA98115C2/ru unknown
- 2007-08-30 DK DK07804880.8T patent/DK2066340T3/da active
- 2007-08-30 NZ NZ595748A patent/NZ595748A/xx unknown
- 2007-08-30 ME MEP-2009-75A patent/ME00598B/me unknown
- 2007-08-30 EP EP11173797.9A patent/EP2377550B1/en active Active
- 2007-08-30 WO PCT/IB2007/002553 patent/WO2008032158A2/en not_active Ceased
- 2007-08-30 AU AU2007297287A patent/AU2007297287B2/en active Active
- 2007-08-30 CN CN200780033767.2A patent/CN101516393B/zh active Active
- 2007-08-30 PL PL07804880T patent/PL2066340T3/pl unknown
- 2007-09-07 US US11/851,951 patent/US8491915B2/en active Active
- 2007-09-10 CL CL200702621A patent/CL2007002621A1/es unknown
- 2007-09-10 TW TW096133683A patent/TWI361077B/zh active
- 2007-09-11 AR ARP070104028A patent/AR062758A1/es not_active Application Discontinuation
-
2009
- 2009-02-16 NO NO20090745A patent/NO339147B1/no unknown
- 2009-03-10 CO CO09024344A patent/CO6160333A2/es unknown
- 2009-04-09 ZA ZA200902493A patent/ZA200902493B/xx unknown
-
2011
- 2011-04-20 RU RU2011115400/10A patent/RU2569457C2/ru active
-
2014
- 2014-01-14 JP JP2014004122A patent/JP5643906B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Friedewald et al. | Low-temperature-grown RS virus in adult volunteers | |
| Kilbourne | Influenza pandemics: can we prepare for the unpredictable? | |
| CL2008003845A1 (es) | Vacuna que comprende una emulsion, una bacterina tratada termicamente a 55-70°c por 5-10 horas, que comprende una suspension de bacterias muertas de la especie leptospira bratislava, y de 1 a 13 virus causantes de enfermedad porcina. | |
| ME00598B (me) | Bakterini tretirani toplotom i vakcine tipa emulzije izrađene od ovakvih bakterina tretiranih toplotom | |
| JP2018534948A5 (me) | ||
| DE69923470T2 (de) | Kombinationsimpfstoff gegen hav und masernvirus und verfahren zu seiner produktion | |
| Schoub | Introduction of inactivated polio vaccine (IPV) into the routine immunization schedule of South Africa | |
| CA2533877A1 (en) | Safe mutant viral vaccines | |
| JP2015519367A5 (me) | ||
| Wang et al. | Research progress of rabies vaccine | |
| Njagi et al. | Effect of immunosuppression on Newcastle disease virus persistence in ducks with different immune status | |
| DE60033291T2 (de) | Multi-komponenten impfstoff zum schutz vor krankheiten die durch haemophilus influenza und moxarella catarrhalis ausgelöst werden | |
| Lehar et al. | Demonstration of 1-year duration of immunity for attenuated Bordetella bronchiseptica vaccines in dogs | |
| WO2008121487A3 (en) | Live attenuated virus vaccines for la crosse virus and other bunyaviridae | |
| Gornatti Churria et al. | Vaccines against Ornithobacterium rhinotracheale: a review | |
| Vidaña et al. | Inactivated pandemic 2009 H1N1 influenza A virus human vaccines have different efficacy after homologous challenge in the ferret model | |
| RU2006133328A (ru) | Способ вакцинации против инфекции семенников bvdv | |
| JP5063116B2 (ja) | 家禽のための混合ワクチン | |
| US11286464B2 (en) | Viral vaccines and methods of forming the same | |
| CN107029230A (zh) | 一种疫苗组合物、试剂盒及其制备方法和应用 | |
| Milić et al. | Overview of current advances in the development of subunit and recombinant vaccines against Newcastle disease virus | |
| Hamouda et al. | Utilization of RT-PCR and restriction enzyme analysis in detection and differentiation of pigeon paramyxovirus-1 and Newcastle disease virus in pigeons | |
| US12435317B2 (en) | Viral vaccines and methods of forming the same | |
| Bharti et al. | Failure of rabies Post-exposure prophylaxis despite achieving adequate antibody titers in a goat at veterinary hospital Rehan | |
| TW201021827A (en) | Adjuvant and vaccine includes the same |